Google
GRCL — GRACELL BIOTECHNOLOGIES INC. (Healthcare >> Biotechnology)
GRCL FAQ
What is GRCL's ROE?
GRACELL BIOTECHNOLOGIES INC. reports a Return on Equity (ROE) of -30.66%.
What is GRCL's dividend yield?
GRACELL BIOTECHNOLOGIES INC. offers a dividend yield of 0.00%.
What is GRCL's Deepscope Quality Score?
Deepscope rates GRCL's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy GRCL?
Deepscope's AI Timing Score for GRCL is 66 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does GRCL belong to?
GRACELL BIOTECHNOLOGIES INC. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 519.90
Price
14.40
(2.85%)
Day Change
|
|
|---|
GRCL, the overall quality is not good ( Quality = 23) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not good , ...
| Quality Factors |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 84 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 519.90 |
| PBV / Sector |
0.61 / 4.63
GREAT
|
| Earning Per Share | -261.03 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
3.21 M
GREAT
|
| Average 1W Daily Value |
1.05 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
50% |
| Ability to Make Profit |
|
47% |
| Return to Investors |
|
8% |
| Registration Details |
| Analyze Date | 2026-06-06 09:08:45 |
| Symbol | GRCL |
| Name | GRACELL BIOTECHNOLOGIES INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 96.57 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 989.87 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Building 12, Block B, Suzhou, China, 215123
Phone: 86 512 6262 6701
Website: https://www.gracellbio.com
Employees: 314
Sector: Healthcare >> Biotechnology
Description: Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in phase 1 clinical trial for the treatment of relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) in adult; and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 2 clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as hematologic cell malignancies and solid tumors. Gracell Biotechnologies Inc. was incorporated in 2017 and is headquartered in Suzhou, China. As of February 22, 2024, Gracell Biotechnologies Inc. operates as a subsidiary of AstraZeneca Treasury Limited.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
